|
With the launch of Lenzelta, Boehringer Ingelheim enhances its comprehensive mastitis portfolio, offering farmers and veterinarians effective solutions to keep their dairy cattle healthy and farms viable. The vaccine will be available in several countries in the European Union (EU) as of April 2026.
Mastitis is among the most widespread and economically significant diseases in dairy cattle. It affects udder health, reduces milk quality and quantity, leading to substantial production losses. For many dairy farms, mastitis-related costs represent one of the highest avoidable economic impacts in their herds3. As cows are particularly vulnerable around calving, preventive strategies during the dry-off period play a crucial role in maintaining herd health and well-being and ensuring a smooth transition into lactation.
Lenzelta targets two key mastitis pathogens, S. aureus and E. coli, supporting farmers and veterinarians in tackling infections proactively. By focusing on prevention at a critical stage of the lactation cycle, the vaccine helps create more stable conditions for milk production and animal well-being.
Lenzelta is administered in two doses during the dry-off period, making it easy to integrate into established herd-health routines. The timing supports an early onset of immunity and provides protection lasting up to six months, covering the period in which cows are most susceptible to mastitis. The vaccine uses an oil-free adjuvant and is available in multiple vial sizes, offering veterinarians flexibility in day-to-day practice.
For veterinarians, Lenzelta offers a practical way to manage mastitis proactively. It supports a preventive approach and enables more sustainable care for dairy herds.
For farmers, Lenzelta can give them back a sense of control, confidence and peace of mind by reducing the prevalence and impact of mastitis infections. The vaccine supports healthier cows, can help strengthen herd productivity and contribute to more reliable milk production and farm operations.
“With Lenzelta, we are setting a new benchmark in mastitis prevention,” says Dr. Gerald Behrens, head of ruminants at Boehringer Ingelheim. “Mastitis places a massive burden on dairy farms around the world. By offering a highly effective vaccine that is easy to integrate into existing routines, we give farmers and veterinarians a powerful new tool to manage one of the industry’s most persistent challenges.”
Starting in April, Lenzelta will be available in several countries across the EU.
Boehringer Ingelheim provides innovation for preventing and treating diseases in animals. The company offers a wide range of vaccines, parasite-control products, and medicines for pets, horses, and livestock to veterinarians, animal owners, farmers, and governments. As a leader in animal health, Boehringer Ingelheim values that the health of humans and animals is deeply connected and strives to make a difference for people, animals, and society.
Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry’s top investors in research and development, the company focuses on developing innovative therapies in areas of high unmet medical need.
|